Cantitate/Preț
Produs

New Developments in Myeloma, An Issue of Hematology/Oncology Clinics of North America: The Clinics: Internal Medicine, cartea 38-2

Editat de Peter Leif Bergsagel
en Limba Engleză Hardback – 29 feb 2024
In this issue of Hematology/Oncology Clinics, guest editor Dr. P. Leif Bergsagel brings his considerable expertise to the topic of New Developments in Myeloma. With the advent of next generation sequencing and immune profiling technologies, marked advances have been made recently in the understanding of the molecular and immune pathogenesis of multiple myeloma. Yet even with these advances, there is a continual search for new therapeutic approaches. In this issue, top experts discuss a full range of clinically relevant topics in this complex and fast-changing field.
Citește tot Restrânge

Din seria The Clinics: Internal Medicine

Preț: 63649 lei

Preț vechi: 66998 lei
-5% Nou

Puncte Express: 955

Preț estimativ în valută:
12185 12531$ 10109£

Carte disponibilă

Livrare economică 29 ianuarie-12 februarie
Livrare express 14-18 ianuarie pentru 4068 lei

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780443130779
ISBN-10: 0443130779
Pagini: 240
Dimensiuni: 152 x 229 x 20 mm
Greutate: 0.62 kg
Editura: Elsevier
Seria The Clinics: Internal Medicine


Cuprins

Molecular Pathogenesis of Multiple Myeloma: Clinical Implications
Immune-Pathogenesis of Myeloma
Smoldering Multiple Myeloma: Observation Versus Control Versus Cure
Cereblon-targeting ligase degraders in myeloma: Mechanisms of action and resistance
Proteasome Inhibitors in Multiple Myeloma: Biological Insights on Mechanisms of Action or Resistance Informed by Functional Genomics
Monoclonal Antibodies in the Treatment of Multiple Myeloma
Bispecific Antibodies in the Treatment of Multiple Myeloma
Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma
Is There Still a Role for Stem Cell Transplantation in Multiple Myeloma?
Role of Consolidation and Maintenance
Management of Newly Diagnosed Multiple Myeloma Today, and in the Future
Impact of Clonal Heterogeneity in Multiple Myeloma
Measurable Residual Disease and Decision-Making in Multiple Myeloma
Approach to High-Risk Multiple Myeloma
New Therapies on the Horizon for Relapsed Refractory Multiple Myeloma
Immunocompetent Mouse Models of Multiple Myeloma: Therapeutic Implications